New class of HIV drug attacks previously untargeted enzyme

A new class of anti-HIV drug which inhibits an as-yet untargeted enzyme in the virus has proven effective in a drug trial, according to an Article in this weeks edition of The Lancet.

There is an urgent need for new antiretroviral drugs due to existing rates of failure in existing combination antiretroviral therapies. The current study looked at the new "integrase-inhibitor" raltegravir when used in conjunction with optimised background combination therapies, in patients with advanced HIV infection whose existing treatments were failing.

There are three types of enzyme essential to the successful replication of HIV reverse-transcriptase, protease and integrase. Integrase is responsible for insertion of HIV DNA into the host cells DNA. Until now all antiretroviral drugs for HIV which target enzymes have been reverse-transcriptase or protease inhibitors.

Dr Bach-Yen Nguyen, Merck Research Laboratories, Westpoint, Pennsylvania, USA, and colleagues divided their patients into four groups. One group received the background treatment plus placebo only, and the other three received the background treatment plus 200, 400 or 600mg of raltegravir twice daily. All 178 patients across the four groups had been receiving antiretroviral therapy for an average of just under 10 years.

The researchers measured the amount of HIV genetic material (HIV RNA) in the blood of patients after 24 weeks, and found that patients taking raltegravir experienced an average of 98% drop in their HIV RNA count, compared to just 45% drop in the placebo group.

The number of CD4 cells which give an indication of the immune response were also significantly boosted in patients taking raltegravir. Patients receiving the 400mg and 600mg doses increased their CD4 count by 113 and 94 cells per ml of blood respectively.

Raltegravir also proved safe, well tolerated and potent in most of the patients.

In related studies of raltegravir*,

Contact: Bach-Yen Nguyen

Page: 1 2

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:

(Date:7/7/2020)... ... July 07, 2020 , ... Dr. Louis M. DeJoseph is ... improve their scalp health. It is now possible to receive Keravive treatments from HydraFacial ... his practice, Dr. DeJoseph is able to provide clients with the best services to ...
(Date:7/7/2020)... , ... July 07, 2020 , ... ... one or two head design to efficiently sanitize large surfaces is now available ... now available to support sales in that region. , In this era of ...
(Date:7/4/2020)... ... ... Houston Life coach, Rashad Garrett, has thrown a lifeline to those struggling with mental ... Faith Of A Mustard Seed (FOAMS). , The global pandemic has caused a drastic ... Federal Agency emergency helpline dedicated to helping people in emotional distress registered more than ...
(Date:7/2/2020)... ... , ... Temprian, a spinoff from Northwestern University, has a ... is vitiligo. Vitiligo patients develop progressive depigmentation of the skin. There is no ... prevalent in all ethnic groups, it is most visible and impactful in people ...
(Date:7/2/2020)... Ala. (PRWEB) , ... July 02, 2020 , ... ... awarded its annual Outstanding Safety Professional of the Year Award to Eric Simmons ... Simmons from more than 250 nominations. Simmons, who holds a master’s degree in ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... ... July 07, 2020 , ... CHESS ... Psych Hub, the leading comprehensive platform for online education on mental health, substance ... resources to Substance Use Disorder (SUD) patients throughout each step of the treatment ...
(Date:7/7/2020)... , ... July 07, 2020 , ... ... 2017, the company began as a hair service provider. Now called Bright, the ... work-from-home employees. Bright’s expanded offering includes beauty amenities as well as an array ...
(Date:7/2/2020)... ... July 02, 2020 , ... ScripHessco has announced ... Treat. , “From migraines to anxiety to fibromyalgia, chiropractors have proven experience ... company. , Sourced from physician recommendations on WebMD, US News, and Advanced ...
Breaking Medicine Technology:
Cached News: